6,324 research outputs found
PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response.
PurposeThe purpose of our study is to determine if there is a relationship between dose deposition measured by PET/MRI and individual lesion response to yttrium-90 ((90)Y) microsphere radioembolization.Materials and methods26 patients undergoing lobar treatment with (90)Y microspheres underwent PET/MRI within 66 h of treatment and had follow-up imaging available. Adequate visualization of tumor was available in 24 patients, and contours were drawn on simultaneously acquired PET/MRI data. Dose volume histograms (DVHs) were extracted from dose maps, which were generated using a voxelized dose kernel. Similar contours to capture dimensional and volumetric change of tumors were drawn on follow-up imaging. Response was analyzed using both RECIST and volumetric RECIST (vRECIST) criteria.ResultsA total of 8 hepatocellular carcinoma (HCC), 4 neuroendocrine tumor (NET), 9 colorectal metastases (CRC) patients, and 3 patients with other metastatic disease met inclusion criteria. Average dose was useful in predicting response between responders and non-responders for all lesion types and for CRC lesions alone using both response criteria (p < 0.05). D70 (minimum dose to 70 % of volume) was also useful in predicting response when using vRECIST. No significant trend was seen in the other tumor types. For CRC lesions, an average dose of 29.8 Gy offered 76.9 % sensitivity and 75.9 % specificity for response.ConclusionsPET/MRI of (90)Y microsphere distribution showed significantly higher DVH values for responders than non-responders in patients with CRC. DVH analysis of (90)Y microsphere distribution following treatment may be an important predictor of response and could be used to guide future adaptive therapy trials
Adequate symptom relief justifies hepatic resection for benign disease
BACKGROUND: The purpose of this study was to evaluate the long-term results of partial liver resection for benign liver lesions. METHODS: All patients operated on for benign liver lesions from 1991 to 2002 were included. Information was retrieved from medical records, the hospital registration system and by a telephonic questionnaire. RESULTS: Twenty-eight patients with a median age of 41 years (17–71) were operated on (M/F ratio 5/23). The diagnosis was haemangioma in 8 patients, FNH in 6, HCA in 13 and angiomyolipoma in 1. Eight patients were known to have relevant co-morbidity. Median operating time was 207 minutes (45–360). The morbidity rate was 25% and no postoperative mortality was observed. Twenty-two patients (79%) had symptoms (mainly abdominal pain) prior to surgery. Twenty-five patients were reached for a questionnaire. The median follow up was 55 months (4–150). In 89% of patients preoperative symptoms had decreased or disappeared after surgery. Four patients developed late complications. CONCLUSION: Long-term follow up after liver surgery for benign liver lesions shows considerable symptom relief and patient satisfaction. In addition to a correct indication these results justify major surgery with associated morbidity and mortality
Total-liver-volume perfusion CT using 3-D image fusion to improve detection and characterization of liver metastases
The purpose of this study
was to evaluate the feasibility of a totalliver-
volume perfusion CT (CTP)
technique for the detection and characterization
of livermetastases. Twenty
patients underwent helical CT of the
total liver volume before and 11 times
after intravenous contrast-material
injection. To decrease distortion artifacts,
all phases were co-registered
using 3-D image fusion before creating
blood-flow maps. Lesion-based sensitivity
and specificity for liver metastases
of first the conventional four
phases (unenhanced, arterial, portal
venous, and equilibrium) and later all
12 phases including blood-flow maps
were determined as compared to intraoperative
ultrasound and surgical exploration.
Arterial and portal venous
perfusion was calculated for normalappearing
and metastatic liver tissue.
Total-liver-volume perfusion values
were comparable to studies using
single-level CTP. Compared to fourphase
CT, total -liver-volume CTP
increased sensitivity to 89.2 from
78.4% (P=0.046) and specificity to
82.6 from 78.3% (P=0.074). Total -
liver-volume CTP is a noninvasive,
quantitative, and feasible technique.
Preliminary results suggest an improved
detection of liver metastases for
CTP compared to four-phase CT
First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study
Ablation; Hepatocellular carcinoma; HistotripsyAblaciĂłn; Carcinoma hepatocelular; HistotriciaAblaciĂł; Carcinoma hepatocel·lular; HistotrĂciaRationale Current hepatic locoregional therapies are limited in terms of effectiveness and toxicities. Given promising pre-clinical results, a first in-human trial was designed to assess the technical effectiveness and safety profile of histotripsy, a noninvasive, non-thermal, non-ionizing focused ultrasound therapy that creates precise, predictable tissue destruction, in patients with primary and secondary liver tumors.
Methods A multicenter phase I trial (Theresa Study) was performed in a single country with 8 weeks of planned follow-up. Eight of fourteen recruited patients were deemed eligible and enrolled in the study. Hepatic histotripsy, was performed with a prototype system (HistoSonics, Inc., Ann Arbor, MI). Eleven tumors were targeted in the 8 patients who all had unresectable end-stage multifocal liver tumors: colorectal liver metastases (CRLM) in 5 patients (7 tumors), breast cancer metastases in 1 (1 tumor), cholangiocarcinoma metastases in 1 (2 tumors), and hepatocellular carcinoma (HCC) in 1 (1 tumor). The primary endpoint was acute technical success, defined as creating a zone of tissue destruction per planned volume assessed by MRI 1-day post-procedure. Safety (device-related adverse events) through 2 months was a secondary endpoint.
Results The 8 patients had a median age of 60.4 years with an average targeted tumor diameter of 1.4 cm. The primary endpoint was achieved in all procedures. The secondary safety profile endpoint identified no device-related adverse events. Two patients experienced a continuous decline in tumor markers during the eight weeks following the procedure.
Conclusions This first-in-human trial demonstrates that hepatic histotripsy effectively destroys liver tissue in a predictable manner, correlating very well with the planned histotripsy volume, and has a high safety profile without any device-related adverse events. Based on these results, the need for more definitive clinical trials is warranted. Trial Registration: Study to Evaluate VORTX Rx (Theresa). NCT03741088. https://clinicaltrials.gov/ct2/show/NCT03741088This study was supported by the funding from Histosonics, Inc
Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver.
Gadoxetate disodium is a widely used magnetic resonance (MR) contrast agent for liver MR imaging, and it provides both dynamic and hepatobiliary phase images. However, acquiring optimal arterial phase images at liver MR using gadoxetate disodium is more challenging than using conventional extracellular MR contrast agent because of the small volume administered, the gadolinium content of the agent, and the common occurrence of transient severe motion. In this article, we identify the challenges in obtaining high-quality arterial-phase images of gadoxetate disodium-enhanced liver MR imaging and present strategies for optimizing arterial-phase imaging based on the thorough review of recent research in this field
Quantitative pretreatment VOI analysis of liver metastases 99mTc-MAA SPECT/CT and FDG PET/CT in relation with treatment response to SIRT
Using quantitive VOI analysis, the percentage Tc-99m-MAA uptake and SUVmax and mean values of liver metastases obtained prior to SIRT were related to treatment response using both a lesion-based and clinical dichotomous approach. Based on the VOI % of Tc-99m-MAA activity, the estimated Y-90-microspheres activity/cc (MBq/cc) was calculated from the effective dose injected. Baseline VOI FDG PET SUVmean and max values and estimated MBq/cc values were related to treatment response using a lesion-based approach (% change in SUVmean >= 50%) and a clinical dichotomous approach. Fifteen treatment sessions were analyzed (13 patients). Using the lesion-based approach (12 treatment sessions) 40 lesions responded and 37 did not. SUVmax and mean values proved significantly different between non-responding and responding lesions; 18:6 (SD 10.8) versus 13.5 (SD 8.4) for SUVmax (p = 0.02) and 11.4 (SD 3.8) versus 6.3 (SD 4.5) for SUVmean (p = 0.002). Using the clinical dichotomous approach (15 treatment sessions / 11 responding), 91 lesions were analyzed; 57 responded. VOI volumes and estimated Y-90-loaded glass microspheres activity (MBq/cc) did not differ between responders and non responders; 24 cc (SD 27) versus 21 cc (SD 21 cc) (p = 0.4) and 1.95 MBq/cc (SD 1.1 MBq/cc) versus 1.90 MB/cc (SD 2.7 MBq/cc) (p = 0.92). On the contrary, SUVmax and mean values proved significantly different between responders and non-responders; 23.7 (SD 9.8) versus 9.4 (SD 3.8) for SUVmax (p = 0.0001) and 13.1 (SD 8.1) versus 4.9 (SD 1.4) for SUVmean. Conclusion: These findings suggest that in patients presenting with high baseline SUVmax and mean values, the administration of higher activities or alternatively, other potentially more useful treatment options might be considered
A quantitative and qualitative analysis of Positron Emission Tomography (PET) in Yttrium-90 radioembolization; investigating the utility of PET dosimetry in identifying sites of necrosis and viable tumor
Purpose: PET imaging is becoming more common for verifying the location of 90Y microspheres during liver cancer treatment. The work aims to predict which patients will likely to have remaining viable tumors based on the 90Y PET image taken right after the radioembolization.
Methods: 10 hepatocellular carcinoma (HCC) patients treated by radioembolization with 90Y glass microspheres were included in this study. Post-treatment PET was coregistered with the follow-up image to investigate the correlation between the isodose contours based on the post-treatment PET image and the necrosis and viable tumor on the follow-up image. To evaluate the similarity quantitatively, isodose contours derived from 90Y PET and necrosis area on the follow-up image were compared using the Dice similarity coefficient. In addition to the quantitative assessment, a qualitative assessment of a 1–5-point scale was utilized to rate the correlation of underdose regions on the post-treatment PET and the viable tumor on the follow-up. The study thereby provided insights into the interpretation and analysis of post-radioembolization imaging in HCC patients.
Results: The findings in this retrospective study with 10 patients included for quantitative assessment suggest an isodose range of 250 Gy to 300 Gy yields the best match for the necrosis site. Also, the qualitative assessment of these 10 patients shows a median agreement of 4 on a 1–5-point scale.
Conclusion: 90Y PET/CT evaluation and dosimetry add clinical benefit to patient treatments by locating untreated tumors and potential sites of recurrence
- …